Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treat
September 11 2007 - 2:50AM
PR Newswire (US)
VALLEY COTTAGE, New York, September 11 /PRNewswire-FirstCall/ --
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) will
hold a conference call today, September 11, 2007, at 8:30 a.m. EDT
to discuss the Phase IIb clinical trial of Bicifadine for the
treatment of diabetic neuropathic pain that was initiated
yesterday. Hosting the call will be Ron Bentsur, XTL's Chief
Executive Officer. Participating on the call will be two
distinguished members of the diabetic neuropathic pain clinical
community: Dr. Christine Sang, Director of Translational Pain
Research at the Brigham and Women's Hospital, Harvard Medical
School, and Chair of XTL's Scientific Advisory Board; and Dr.
Andrew Boulton, Professor of Medicine at the Diabetes Research
Institute, University of Miami, and at the University of Manchester
in the United Kingdom, Chair of the American Diabetes Association
Foot Care Interest Group, and a co-lead investigator in the
Bicifadine study. In order to participate in the conference call,
please call +1-877-502-9272 (in the United States), +1-913-981-5581
(outside the United States), call in passcode: 2040477. An audio
recording of the conference call will be available for replay by
calling +1-888-203-1112 (in the United States), +1-719-457-0820
(outside the United States), replay passcode 2040477, for a period
of 45 days after the call. About XTL Biopharmaceuticals Ltd. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C.
XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain.
XTL is also developing several novel pre-clinical hepatitis C small
molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel- Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL).
Contact: Ron Bentsur Chief Executive Officer Tel: +1-(845)-267-0707
ext. 225 DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact:
Ron Bentsur, Chief Executive Officer, Tel: +1-(845)-267-0707 ext.
225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024